VolitionRx Showcases Innovations at Asian Veterinary Conference with Two Key Presentations
VolitionRx Showcases Innovations at AMAMS 2025
VolitionRx Limited, a global leader in the field of epigenetics, has announced its active participation in the Asian Meeting of Animal Medicine Specialties (AMAMS) 2025, which is set to take place in Thailand. During this prominent veterinary event, the company will deliver two significant oral presentations centered around its innovative Nu.Q® Vet Cancer Test.
The presentations will be led by Dr. Masahiko Sato, a highly respected figure in the veterinary community. Dr. Sato holds multiple credentials, including DVM, PhD, DACVIM (SAIM), and DAiCVIM (IM), and serves as the Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of Japan's leading referral hospitals. His collaboration with FujiFilm Vet Systems underscores the importance of these findings and their implications for veterinary medicine.
Highlighted Presentations
1. Diagnostic Utility of Plasma Nucleosome Concentration
- - Presenter: Kentaro Nabeshima
- - Date & Time: Thursday, June 5, 2025, from 2:00 PM to 3:00 PM ICT
- - Venue: Room 108
This presentation focuses on the diagnostic potential of the Nu.Q® Vet Cancer Test, particularly in distinguishing between Canine Chronic Enteropathy (CE) and Gastrointestinal Lymphoma (GIL). The findings suggest that the Nu.Q® Vet Cancer Test could act as a vital diagnostic tool, especially in cases where conventional methods may not provide clarity. Particularly noteworthy are the higher plasma nucleosome levels observed in medium-to-large cell GIL, highlighting the test's sensitivity and specificity.
Dr. Sato expressed optimism regarding the impact of the Nu.Q® Vet Cancer Test, stating, "The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma."
2. Evaluation of Plasma Nucleosome Concentrations in Canine Nasal Tumors
- - Presenter: Chihoko Takahashi
- - Date & Time: Thursday, June 5, 2025, from 3:30 PM to 3:40 PM ICT
- - Venue: Room 108
This segment of the presentation will delve into how plasma nucleosome concentrations can serve as biomarkers for canine nasal tumors, further establishing the Nu.Q® Vet Cancer Test as a multifaceted tool for veterinarians when diagnosing various oncological conditions in pets.
Kiyotaka Fujiwara, the Chief Operating Officer at FujiFilm Vet Systems, expressed delight at the recognition of the Nu.Q® Vet Cancer Test in Japan, stating, “We are thrilled that Dr. Sato is not only adopting this test but is also publishing specific case studies that will enhance awareness and acceptance of this diagnostic tool within the veterinary community.”
About VolitionRx
Volition is dedicated to advancing the field of epigenetics with a mission to improve detection and monitoring of diseases in both humans and animals. The company is at the forefront of developing and commercializing user-friendly, cost-effective blood tests aimed at early disease detection—critical for enhancing patient outcomes. The central research and development hub is located in Belgium, with additional offices in the United States and London.
Through efforts like participation in events such as AMAMS 2025, VolitionRx continues to contribute to improving veterinary practices and enhancing methodologies for diagnosing life-changing diseases in animals. The ultimate goal is not only to prolong lives but also to enhance the quality of life for pets and their owners.
For more updates from this event, please stay tuned.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.